, Volume 186, Issue 3, pp 151–156

Plasminogen Activator Inhibitor-1 in Obstructive Sleep Apnea Patients with and without Hypertension

  • Carlos Zamarrón
  • Jorge Ricoy
  • Alberto Riveiro
  • Francisco Gude


Obstructive sleep apnea syndrome (OSAS) is an important risk factor in cardiovascular disorders. Although the precise mechanism remains to be described, hypercoagulability seems to be involved. To test the presence of decreased fibrinolysis, we measured plasma levels of plasminogen activator inhibitor-1 (PAI-1) in 96 male subjects (32 subjects with OSAS, 32 subjects with both OSAS and hypertension, and a 32 subjects in the control group). All subjects completed a sleep questionnaire and underwent a general physical examination, biochemistry test, and polysomnography study. Patients and control subjects had similar baseline clinical characteristics for age, gender, smoking habit, and levels of cholesterol and triglycerides. Patients with OSAS presented significantly higher circulating levels of PAI-1 compared with the control group, and the difference was even more marked in patients with both OSAS and hypertension. OSAS patients presented a significant inverse correlation between PAI-1 levels and apnea-hypopnea index (r = −0.71, p < 0.001). In conclusion, OSAS patients presented higher circulating levels of PAI than the control group, which was even greater when patients had associated hypertension.


Sleep apnea syndrome Plasminogen activator inhibitor-1 Hypertension Cardiovascular diseases Fibrinolysis 


  1. 1.
    Remmers JE, deGroot WJ, Sauerland EK, Anch AM (1978) Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 44:931–938PubMedGoogle Scholar
  2. 2.
    Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235CrossRefPubMedGoogle Scholar
  3. 3.
    Pichel F, Zamarron C, Magán F, del Campo F, Alfarez-Sala R, Suarez JR (2004) Health-related quality of life in patients with obstructive sleep apnea: effects of long-term positive airway pressure treatment. Respir Med 98:968–976CrossRefPubMedGoogle Scholar
  4. 4.
    Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J (1999) The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 340:847–851CrossRefPubMedGoogle Scholar
  5. 5.
    Coccagna G, Pollini A, Provini F (2006) Cardiovascular disorders and obstructive sleep apnea syndrome. Clin Exp Hypertens 28:217–224CrossRefPubMedGoogle Scholar
  6. 6.
    Lavie L (2005) Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 23:1059–1075CrossRefPubMedGoogle Scholar
  7. 7.
    Suzuki YJ, Jain V, Park AM, Day RM (2006) Oxidative stress and oxidant signaling in obstructive sleep apnea and associated cardiovascular diseases. Free Radic Biol Med 40:1683–1692CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schulz R (2005) The vascular micromilieu in obstructive sleep apnoea. Eur Respir J 25:780–782CrossRefPubMedGoogle Scholar
  9. 9.
    Juhan-Vague I, Alessi MC, Vague P (1996) Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28:371–380CrossRefPubMedGoogle Scholar
  10. 10.
    Saigo M, Hsue PY, Waters DD (2004) Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis 46:524–538CrossRefPubMedGoogle Scholar
  11. 11.
    Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padró T (2006) Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 6:439–456CrossRefPubMedGoogle Scholar
  12. 12.
    Wessendorf TE, Thilmann AF, Wang YM, Schreiber A, Konietzko N, Teschler H (2000) Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 162:2039–2042CrossRefPubMedGoogle Scholar
  13. 13.
    Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W (2000) Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 16:648–652CrossRefPubMedGoogle Scholar
  14. 14.
    Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M (2002) In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 69:229–234CrossRefPubMedGoogle Scholar
  15. 15.
    Hui DS, Ko FW, Fok JP, Chan MC, Li TS, Tomlinson B, Cheng G (2004) The effects of nasal continuous positive airway pressure on platelet activation in obstructive sleep apnea syndrome. Chest 125:1768–1775CrossRefPubMedGoogle Scholar
  16. 16.
    Guardiola JJ, Matheson PJ, Clavijo LC, Wilson MA, Fletcher EC (2001) Hypercoagulability in patients with obstructive sleep apnea. Sleep Med 2:517–523CrossRefPubMedGoogle Scholar
  17. 17.
    Von Kanel R, Dimsdale JE (2003) Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 124:1956–1967CrossRefGoogle Scholar
  18. 18.
    Chmielewska J, Ranby M, Wiman B (1983) Evidence for a rapid inhibitor to tPA in plasma. Thromb Res 31:427–436CrossRefPubMedGoogle Scholar
  19. 19.
    Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527–3561PubMedGoogle Scholar
  20. 20.
    Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Anglès-Cano E, Lijnen HR (2006) Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4:664–670CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, Fujii S, Tsutsui H, Tamaki N (2007) Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J 71:348–353CrossRefPubMedGoogle Scholar
  22. 22.
    Von Känel R, Loredo JS, Ancoli-Israel S, Dimsdale JE (2007) Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 131:733–739CrossRefGoogle Scholar
  23. 23.
    Mannucci PM, Gringeri A, Peyvandi F, Di Paolantonio T, Mariani G (2002) Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thromb Haemost 87:342–343PubMedGoogle Scholar
  24. 24.
    Toff WD, Jones CI, Ford I, Pearse RJ, Watson HG, Watt SJ, Ross JA, Gradwell DR, Batchelor AJ, Abrams KR, Jeijers JC, Goodall AH, Greaves M (2006) Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. JAMA 295:2251–2261CrossRefPubMedGoogle Scholar
  25. 25.
    Gertler JP, Weibe DA, Ocasio VH, Abbott WM (1991) Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vasc Surg 13:428–433CrossRefPubMedGoogle Scholar
  26. 26.
    Liao H, Hyman MC, Lawrence DA, Pinsky DJ (2007) Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 21:935–949CrossRefPubMedGoogle Scholar
  27. 27.
    Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K (1995) Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 18:188–194CrossRefPubMedGoogle Scholar
  28. 28.
    Barcelo A, Llompart E, Barbe F, Morlá M, Vila M, Agusti AG (2002) Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea. Respir Med 96:193–196CrossRefPubMedGoogle Scholar
  29. 29.
    Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague J (1994) Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 72:44–53 PubMedGoogle Scholar
  30. 30.
    Venugopal B, Sharon R, Abramovitz R, Khasin A, Miskin R (2001) Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction alter injecting mice with kainate or adrenergic agents. Cardiovasc Res 49:476–483CrossRefPubMedGoogle Scholar
  31. 31.
    Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG (2006) Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 100:343–348CrossRefPubMedGoogle Scholar
  32. 32.
    Von Kanel R, Loredo JS, Ancoli-Israel S, Dimsdale JE (2006) Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 10:139–146CrossRefGoogle Scholar
  33. 33.
    Shatos MA, Doherty JM, Stump DC, Thompson EA, Collen D (1990) Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture. J Biol Chem 265:20443–20448PubMedGoogle Scholar
  34. 34.
    Juhan-Vague I, Alessi MC, Mavri A, Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575–1579CrossRefPubMedGoogle Scholar
  35. 35.
    Mertens I, Van der Planken M, Corthouts B, Van Gaal LF (2001) Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33:602–607CrossRefPubMedGoogle Scholar
  36. 36.
    Sundell IB, Dahlen GH, Ranby M (1991) Diet-induced changes in glucose and triglycerides are associated with changes in plasminogen activator inhibitor levels. Haemostasis 21:175–180PubMedGoogle Scholar
  37. 37.
    Fogari R, Zoppi A (2006) Antihypertensive drugs and fibrinolytic function. Am J Hypertens 19:1293–1299CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Carlos Zamarrón
    • 1
  • Jorge Ricoy
    • 1
  • Alberto Riveiro
    • 2
  • Francisco Gude
    • 3
  1. 1.Division of Respiratory MedicineHospital Clínico Universitario de SantiagoSantiago de CompostelaSpain
  2. 2.Department of BiochemistryHospital Clínico Universitario de SantiagoSantiago de CompostelaSpain
  3. 3.Epidemiology UnitHospital Clínico Universitario de SantiagoSantiago de CompostelaSpain

Personalised recommendations